SAN DIEGO, Oct. 13, 2017 /PRNewswire/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) announced today that the United States District Court for the District of Delaware issued a ruling in favor of ...
Orexigen Therapeutics Receives Dispute Response Indicating FDA is Highly Supportive of Exploration of a Faster Path to Resubmission of the Contrave NDA -- Light Study enrollment surpasses 7,000 ...
Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX), today announced that it has implemented a corporate realignment of the Company's workforce, resulting in a reduction in staff of approximately 40%, or 23 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results